Allogene Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $22 |
Gross Profit | -3,644 | -3,533 | ||
EBITDA | -56,182 | -62,986 | -62,798 | -65,949 |
EBIT | -59,415 | -66,193 | -66,442 | -69,504 |
Net Income | -59,939 | -66,293 | -66,358 | -65,000 |
Net Change In Cash | 0 | 0 | 0 | 22 |
Free Cash Flow | -36,955 | -44,544 | -63,588 | -55,907 |
Cash | 75,218 | 51,239 | 170,667 | 51,039 |
Basic Shares | 210,572 | 209,188 | 190,026 | 169,128 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $22 | $95 | $243 | $38,489 |
Gross Profit | 22 | -242,819 | 243 | 38,489 |
EBITDA | -243,327 | -300,293 | -321,154 | -245,338 |
EBIT | -256,966 | -314,492 | -335,449 | -255,792 |
Net Income | -257,590 | -327,265 | -329,815 | -244,837 |
Net Change In Cash | 22 | 95 | 243 | 38,489 |
Cost of Revenue | -9,194 | |||
Free Cash Flow | -200,994 | -239,249 | -225,710 | -206,258 |
Cash | 75,218 | 83,155 | 576,471 | 809,481 |
Basic Shares | 194,811 | 156,931 | 143,147 | 135,820 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.28 |
2024-09-30 | -$0.32 |
2024-06-30 | -$0.35 |
2024-03-31 | -$0.38 |
